A new antidiabetic agent improves memory impairment in Alzheimer’s disease

lisafx/epictura

Published the 03.01.2018 at 17h32

A A

Keywords :

disease alzheimerAntidiabétiqueneuroprotectionmémoire

The study, published in Brain Research, making a lot of noise because it might substantially improve the treatment of Alzheimer’s disease. And this thanks to the use of a drug originally created to treat type 2 diabetes.
According to Doug Brown, director of research and development, the International Society on Alzheimer’s disease, said : “Without any new treatment in nearly 15 years, we need to find new avenues to fight against Alzheimer’s disease. It is imperative that we should explore whether drugs developed to treat other diseases may not benefit to people with Alzheimer’s disease and other forms of dementia “.
This research approach could also make it a lot faster getting promising new drugs to people who need it.

A agonist treatment triple

Although the benefits of the antidiabetic drug, is an agonist triple, is for the time being observed that in mice, further studies on existing drugs such as liraglutide have shown in the past a real interest in people suffering from Alzheimer’s disease.
This medication agonist triple is multiple ways to protect the brain from degeneration. It combines an agonist effect on receptors of GLP-1, GIP, and Glucagon, all of which are factors of growth.
It has, indeed, been demonstrated in the past that the growth factor signaling is altered in the brain of patients with Alzheimer’s disease.

An animal model of Alzheimer’s disease

Transgenic mice APP/PS1 with advanced stages of neurodegeneration of the Alzheimer type have been subjected to treatment in this study.
These transgenic mice express the mutated genes responsible human Alzheimer’s disease. These genes are those that have been found in the families of individuals who have a hereditary form of Alzheimer’s disease.
In these mice, the tests of the labyrinth, learning, and memory formation have been extensively improved by the triple agonist, which increases the level of a growth factor in the brain, which protects the functioning of nerve cells, reduces the amount of amyloid plaques in the brain linked to Alzheimer’s disease, reduces both the chronic inflammation and oxidative stress and slows the loss of nerve cells

Close links diabetes and Alzheimer’s disease

Type 2 diabetes is an important risk factor of Alzheimer’s disease and it has been implicated in the progression of the disease. The decrease in the secretion of insulin has been associated with degenerative processes of brain that are common in type 2 diabetes, and Alzheimer’s disease.
Insulin resistance has also been observed in the brain of patients with Alzheimer’s disease. This resistance could play a role in the development of neurodegenerative disorders as insulin is a growth factor with neuroprotective properties.
Clinical studies with anti-diabetic older had already shown very promising results in people with Alzheimer’s disease or mood disorders. The new antidiabetic agent with a triple agonism is promising as a potential treatment of Alzheimer’s disease, but further studies are required before affirming it.

The results of these new drug antagonists, multiple, originally developed to treat type 2 diabetes, are very promising as they have shown neuroprotective effects consistent in several studies.